Follow
Miriam Molina Arcas
Miriam Molina Arcas
Verified email at crick.ac.uk
Title
Cited by
Cited by
Year
Oncogenic RAS signaling promotes tumor immunoresistance by stabilizing PD-L1 mRNA
MA Coelho, S de Carné Trécesson, S Rana, D Zecchin, C Moore, ...
Immunity 47 (6), 1083-1099. e6, 2017
5292017
The GATA2 transcriptional network is requisite for RAS oncogene-driven non-small cell lung cancer
MS Kumar, DC Hancock, M Molina-Arcas, M Steckel, P East, ...
Cell 149 (3), 642-655, 2012
3102012
Nucleoside transporter profiles in human pancreatic cancer cells: role of hCNT1 in 2′, 2′-difluorodeoxycytidine-induced cytotoxicity
J García-Manteiga, M Molina-Arcas, FJ Casado, A Mazo, ...
Clinical Cancer Research 9 (13), 5000-5008, 2003
2662003
Pandemic peak SARS-CoV-2 infection and seroconversion rates in London frontline health-care workers
CF Houlihan, N Vora, T Byrne, D Lewer, G Kelly, J Heaney, S Gandhi, ...
The Lancet 396 (10246), e6-e7, 2020
2482020
Nucleoside transporter proteins
M Molina-Arcas, FJ Casado, M Pastor-Anglada
Current vascular pharmacology 7 (4), 426-434, 2009
2042009
Determination of synthetic lethal interactions in KRAS oncogene-dependent cancer cells reveals novel therapeutic targeting strategies
M Steckel, M Molina-Arcas, B Weigelt, M Marani, PH Warne, H Kuznetsov, ...
Cell research 22 (8), 1227-1245, 2012
1992012
Development of combination therapies to maximize the impact of KRAS-G12C inhibitors in lung cancer
M Molina-Arcas, C Moore, S Rana, F Van Maldegem, E Mugarza, ...
Science translational medicine 11 (510), eaaw7999, 2019
1772019
Coordinate Direct Input of Both KRAS and IGF1 Receptor to Activation of PI3 kinase in KRAS-Mutant Lung Cancer
M Molina-Arcas, DC Hancock, C Sheridan, MS Kumar, J Downward
Cancer discovery 3 (5), 548-563, 2013
1772013
Cell entry and export of nucleoside analogues
M Pastor-Anglada, P Cano-Soldado, M Molina-Arcas, MP Lostao, ...
Virus research 107 (2), 151-164, 2005
1692005
Transport of lamivudine [(-)-β-l-2′, 3′-dideoxy-3′-thiacytidine] and high-affinity interaction of nucleoside reverse transcriptase inhibitors with human organic cation …
G Minuesa, C Volk, M Molina-Arcas, V Gorboulev, I Erkizia, P Arndt, ...
Journal of pharmacology and experimental therapeutics 329 (1), 252-261, 2009
1622009
Estimating the effectiveness of routine asymptomatic PCR testing at different frequencies for the detection of SARS-CoV-2 infections
J Hellewell, TW Russell, R Beale, G Kelly, C Houlihan, E Nastouli, ...
BMC medicine 19, 1-10, 2021
1422021
Fludarabine uptake mechanisms in B-cell chronic lymphocytic leukemia
M Molina-Arcas, B Bellosillo, FJ Casado, E Montserrat, J Gil, D Colomer, ...
Blood, The Journal of the American Society of Hematology 101 (6), 2328-2334, 2003
1392003
Nucleoside transporters in chronic lymphocytic leukaemia
M Pastor-Anglada, M Molina-Arcas, FJ Casado, B Bellosillo, D Colomer, ...
Leukemia 18 (3), 385-393, 2004
1372004
RAC1P29S induces a mesenchymal phenotypic switch via serum response factor to promote melanoma development and therapy resistance
DA Lionarons, DC Hancock, S Rana, P East, C Moore, MM Murillo, ...
Cancer cell 36 (1), 68-83. e9, 2019
1142019
Expression of human equilibrative nucleoside transporter 1 (hENT1) and its correlation with gemcitabine uptake and cytotoxicity in mantle cell lymphoma
S Marcé, M Molina-Arcas, N Villamor, FJ Casado, E Campo, ...
Haematologica 91 (7), 895-902, 2006
962006
Antibodies against endogenous retroviruses promote lung cancer immunotherapy
KW Ng, J Boumelha, KSS Enfield, J Almagro, H Cha, O Pich, T Karasaki, ...
Nature 616 (7957), 563-573, 2023
892023
Equilibrative nucleoside transporter-2 (hENT2) protein expression correlates with ex vivo sensitivity to fludarabine in chronic lymphocytic leukemia (CLL) cells
M Molina-Arcas, S Marce, N Villamor, I Huber-Ruano, FJ Casado, ...
Leukemia 19 (1), 64-68, 2005
842005
Expression and functionality of anti-human immunodeficiency virus and anticancer drug uptake transporters in immune cells
G Minuesa, S Purcet, I Erkizia, M Molina-Arcas, M Bofill, ...
Journal of Pharmacology and Experimental Therapeutics 324 (2), 558-567, 2008
822008
RAS signalling through PI3-Kinase controls cell migration via modulation of Reelin expression
E Castellano, M Molina-Arcas, AA Krygowska, P East, P Warne, A Nicol, ...
Nature communications 7 (1), 11245, 2016
682016
SHOC2 phosphatase-dependent RAF dimerization mediates resistance to MEK inhibition in RAS-mutant cancers
GG Jones, IB Del Río, S Sari, A Sekerim, LC Young, N Hartig, ...
Nature communications 10 (1), 2532, 2019
632019
The system can't perform the operation now. Try again later.
Articles 1–20